Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Proteus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Proteus. Displaying page 1 of 1.
    EudraCT Number: 2021-001369-19 Sponsor Protocol Number: MK-7075-006 Start Date*: 2021-10-20
    Sponsor Name:MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.
    Full Title: A Multicenter, Open-label, Phase 2, Extension Trial to Study the Long-term Safety in Participants With PROS or Proteus Syndrome Who Are Currently Being Treated with Miransertib in Other Studies
    Medical condition: PIK3CA-related overgrowth spectrum (PROS) and Proteus Syndrome (PS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10010331 - Congenital, familial and genetic disorders 10081236 PIK3CA related overgrowth spectrum PT
    20.0 10010331 - Congenital, familial and genetic disorders 10074067 Proteus syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003640-23 Sponsor Protocol Number: ECR-RET-2013-05 Start Date*: 2014-01-13
    Sponsor Name:AIBILI - Association for Innovation and Biomedical Research on Light and Image
    Full Title: Prospective, randomized, multicentre, open label, phase II / III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP ...
    Medical condition: Patients with type I or type II diabetes mellitus and high risk diabetic retinopathy.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10036857 Proliferative diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000558-37 Sponsor Protocol Number: ARQ092-103 Start Date*: 2017-02-22
    Sponsor Name:ArQule, Inc.
    Full Title: A Phase 1/2 Study of ARQ 092 in Patients with Overgrowth Diseases and Vascular Anomalies with Genetic Alterations of the PI3K/AKT Pathway
    Medical condition: subjects (at least 6 years) suffering from diseases overgrowth and vascular anomalies with genetic alterations of the PI3K / AKT pathway.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) FR (Ongoing) ES (Temporarily Halted) GB (GB - no longer in EU/EEA) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003402-25 Sponsor Protocol Number: OCT-UKE-2011 Start Date*: 2011-12-13
    Sponsor Name:Schülke & Mayr GmbH
    Full Title: Randomized, Double-blind, Single-center, Placebo-controlled Study to evaluate the Efficacy of octenisept® in Patients with Chronic Wounds.
    Medical condition: Chronic leg ulcers
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004858 10068310 Leg ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001590-24 Sponsor Protocol Number: 01.01.18 Start Date*: 2019-03-21
    Sponsor Name:University of Dundee [...]
    1. University of Dundee
    2. NHS Tayside
    Full Title: A Trial of the Safety, Tolerability and Efficacy of 2 doses of Cayston (Aztreonam Lysine) compared to placebo in participants with bronchiectasis.
    Medical condition: Bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038738 - Respiratory, thoracic and mediastinal disorders 10006445 Bronchiectasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2016-004501-14 Sponsor Protocol Number: EDC-3135 Start Date*: Information not available in EudraCT
    Sponsor Name:ZOLL, Inc.
    Full Title: COOL-AMI EU PIVOTAL TRIAL: A MULTICENTER, PROSPECTIVE, RANDOMIZED- CONTROLLED TRIAL TO ASSESS THE SAFETY AND EFFECTIVENESS OF COOLING AS AN ADJUNCTIVE THERAPY TO PERCUTANEOUS INTERVENTION INP A TIE...
    Medical condition: Acute Myocardial Infarction
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005416-15 Sponsor Protocol Number: SIPA-SOS Start Date*: 2016-10-20
    Sponsor Name:Medical Center - University of Freiburg [...]
    1. Medical Center - University of Freiburg
    2. Medical Center - University of Freiburg
    Full Title: An open label phase II study of Sirolimus in patients with segmental overgrowth syndrome
    Medical condition: Segmental overgrowth syndrome
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001746-34 Sponsor Protocol Number: 56021927PCR3011 Start Date*: 2019-04-02
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy
    Medical condition: High-risk localized or locally advanced prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) DE (Ongoing) NL (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:02:26 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA